130 related articles for article (PubMed ID: 21469498)
21. Nephrogenic diabetes insipidus induced by two amphotericin B liposomal formulations.
Metzger NL; Varney Gill KL
Pharmacotherapy; 2009 May; 29(5):613-20. PubMed ID: 19397468
[TBL] [Abstract][Full Text] [Related]
22. Lipid-based formulations of amphotericin B.
Plotnick AN
J Am Vet Med Assoc; 2000 Mar; 216(6):838-41. PubMed ID: 22570893
[No Abstract] [Full Text] [Related]
23. Lipid-covered drug particles: combined action of dioctadecyldimethylammonium bromide and amphotericin B or miconazole.
Lincopan N; Carmona-Ribeiro AM
J Antimicrob Chemother; 2006 Jul; 58(1):66-75. PubMed ID: 16636081
[TBL] [Abstract][Full Text] [Related]
24. [Amphotericin B: the end of an era].
Oude Lashof AM; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
[TBL] [Abstract][Full Text] [Related]
25. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
[TBL] [Abstract][Full Text] [Related]
26. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.
Craddock C; Anson J; Chu P; Dodgson A; Duncan N; Gomez C; Mehta J; Sadullah S; Subudhi C; Yin JL
Expert Opin Drug Saf; 2010 Jan; 9(1):139-47. PubMed ID: 19947901
[TBL] [Abstract][Full Text] [Related]
27. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
28. Amphotericin B lipid complex and respiratory distress.
Shuster J
Nursing; 1999 Mar; 29(3):70. PubMed ID: 10205512
[No Abstract] [Full Text] [Related]
29. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
30. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
31. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model.
Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
Eur J Pharm Sci; 2012 Aug; 46(5):323-8. PubMed ID: 22369857
[TBL] [Abstract][Full Text] [Related]
32. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
33. Comparison between liposomal formulations of amphotericin B.
Adler-Moore JP; Gangneux JP; Pappas PG
Med Mycol; 2016 Mar; 54(3):223-31. PubMed ID: 26768369
[TBL] [Abstract][Full Text] [Related]
34. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.
Tonin FS; Steimbach LM; Borba HH; Sanches AC; Wiens A; Pontarolo R; Fernandez-Llimos F
J Pharm Pharmacol; 2017 Dec; 69(12):1672-1683. PubMed ID: 28815602
[TBL] [Abstract][Full Text] [Related]
36. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
37. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
38. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
Rowles DM; Fraser SL
Clin Infect Dis; 1999 Dec; 29(6):1564-5. PubMed ID: 10585814
[TBL] [Abstract][Full Text] [Related]
39. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
[TBL] [Abstract][Full Text] [Related]
40. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
